A magnetic enteric-coated tablet containing diclofenac sodium was produced, and its performance under physiological and disturbed gastrointestinal motility was assessed through pharmacomagnetography analysis. In vitro studies were performed using conventional methods and in vivo studies were conducted on healthy volunteers before (control) and after domperidone administration. The magnetic tablet's gastrointestinal (GI) transit and disintegration process were monitored using the Alternating Current Biosusceptometry sensors combined with drug plasmatic concentration. The Gastric Residence Time, Colon Arrival Time, Small Bowel Transit Time, Disintegration Time and the pharmacokinetics parameters were calculated. The pH-dependent polymers used to coat the magnetic tablets were able to avoid the premature drug release on gastric or small intestine simulated medium. Gastric Residence Time was accelerated compared with the control group (p < 0.01). No significant differences were found regarding small bowel transit, colon arrival, disintegration process, or pharmacokinetics parameters. A strong correlation between magnetic monitoring and pharmacokinetics parameters analysis was determinant to evaluate the efficiency in the drug delivery at a specific site in the human gastrointestinal tract. In addition, a tablet with a damaged coating was used as a proof of concept to show the suitability of our methodology to evaluate the tablet. Our study showed that pharmacomagnetography is a multi-instrumental approach towards assessing drug delivery and bioavailability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpb.2021.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical study of different frequency transcranial magnetic stimulation combined with paroxetine in the treatment of poststroke depression with insomnia.
Medicine (Baltimore)
November 2024
Sleep Medicine Department, Hebei Provincial Mental Health Center, The Sixth People's Hospital of Hebei Province, Baoding, Hebei, People's Republic of China.
Background: Study the treatment of poststroke depression and insomnia using varied repetitive transcranial magnetic stimulation (rTMS) frequencies alongside paroxetine. Aim to enhance rTMS effectiveness for depression, insomnia, neurological impairment, and daily living skills.
Methods: Ninety poststroke depression (PSD) patients were randomly divided into a low-frequency group (low-frequency rTMS + enteric-coated paroxetine), a high-frequency group (high-frequency rTMS + enteric-coated paroxetine), and a control group (sham stimulation + enteric-coated paroxetine).
A Chinese CADASIL family with a rare heterozygous mutation in exon 2 of NOTCH3: A case report.
Medicine (Baltimore)
October 2024
Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Rationale: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease caused by the neurogenic locus notch homolog protein 3 (NOTCH3) gene mutation. In recent years, most of the newly reported mutations of CADASIL patients mainly occur in exon 3 to 24, while the cases related to exon 2 mutation are rare, and clinical research data are relatively insufficient. In this study, we have reported a case of a rare heterozygous mutation c.
View Article and Find Full Text PDFEnteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum.
Mol Pharm
June 2024
Institute of Pharmacy, University of Greifswald, Greifswald 17487, Germany.
Nefecon, a targeted-release capsule formulation of budesonide approved for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, targets overproduction of galactose-deficient immunoglobulin A type 1 in the Peyer's patches at the gut mucosal level. To investigate whether the commercial formulation of Nefecon capsules reliably releases budesonide to the distal ileum, a human study was conducted with test capsules reproducing the delayed-release function of Nefecon capsules. Caffeine was included in the test capsules as a marker for capsule opening in the gut since it appears rapidly in saliva after release from orally administered dosage forms.
View Article and Find Full Text PDFAGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.
Gastroenterology
November 2023
Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida.
Article Synopsis
- Exocrine pancreatic insufficiency (EPI) is a condition where the pancreas fails to provide enough digestive enzymes, leading to nutrient maldigestion and potential deficiencies, and it is often underdiagnosed.
- The American Gastroenterological Association (AGA) created a Clinical Practice Update to improve awareness and management of EPI among healthcare professionals.
- Best Practice Advice from the review includes identifying high-risk patients (like those with chronic pancreatitis or pancreatic cancer) and considering EPI in those with moderate-risk conditions (like celiac disease or diabetes).
Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor: A case report.
World J Clin Cases
July 2022
Department of General Surgery, ASST Papa Giovanni XXIII Hospital, Bergamo 24127, Italy.
Background: Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon. Before dissolution of the enteric coating, they may appear hyperdense on computed tomography (CT). Unfortunately, few reports have been published on this topic so far.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!